• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Quantitative analysis of genetic factors affecting the extent of drug interactions via mechanism based inhibition of cytochrome P450

Research Project

Project/Area Number 24590668
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Applied pharmacology
Research InstitutionKeio University

Principal Investigator

OHTANI Hisakazu  慶應義塾大学, 薬学部, 教授 (70262029)

Co-Investigator(Kenkyū-buntansha) YAMAMOTO Koujirou  群馬大学, 医学部, 教授 (70174787)
Co-Investigator(Renkei-kenkyūsha) AKIYOSHI Takeshi  慶應義塾大学, 薬学部, 助教 (50399143)
YAMAZAKI Hiroshi  昭和薬科大学, 薬学部, 教授 (30191274)
Project Period (FY) 2012-04-01 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords薬物相互作用 / 個人差 / テーラーメード医療 / 不可逆的阻害 / 遺伝子多型 / テーラーメイド薬物治療 / テーラーメード薬物治療
Outline of Final Research Achievements

There seems to be considerable inter-individual variations in the extent of drug interactions, especially via the inhibition of oxidative metabolic enzymes, P450s. This study aimed to investigate quantitatively the influence of genetic variation of P450s, such as CYP3A4 and CYP2D6, on the extent of drug interaction in the in vitro studies using genetic variants. As a result of enzymatic study with probe substrates and mechanism-based inhibitors (MBI), we concluded that the inhibitory potencies of MBI differ among genetic variants. These results suggest that the genetic variation of metabolic enzymes affect the extent of drug interactions caused by their inhibitors, as well as the pharmacokinetics of their substrate drugs.

Report

(4 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • 2012 Research-status Report
  • Research Products

    (11 results)

All 2015 2014 2013

All Journal Article (3 results) (of which Peer Reviewed: 3 results,  Open Access: 1 results,  Acknowledgement Compliant: 1 results) Presentation (8 results)

  • [Journal Article] Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D62015

    • Author(s)
      Takeshi Akiyoshi, Miho Ishiuchi, Ayuko Imaoka, and Hisakazu Ohtani
    • Journal Title

      Drug Metabol Pharmacokinet

      Volume: in press

    • NAID

      50014429969

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant
  • [Journal Article] Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants.2013

    • Author(s)
      114. T. Akiyoshi, M. Ito, S. Murase, M. Miyazaki, F.P. Guengerich, K. Nakamura, K. Yamamoto, H. Ohtani
    • Journal Title

      Drug Metabol. Pharmacokinet

      Volume: 25(5) Pages: 411-415

    • NAID

      130004933542

    • Related Report
      2013 Research-status Report
    • Peer Reviewed
  • [Journal Article] Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants2013

    • Author(s)
      Takeshi Akiyoshi, Marie Ito, Saori Murase, Mitsue Miyazaki, F. Peter Guengerich, Katsunori Nakamura, Koujirou Yamamoto and Hisakazu Ohtani
    • Journal Title

      Drug Metabol Pharmacokinet

      Volume: 28

    • NAID

      130004933542

    • Related Report
      2012 Research-status Report
    • Peer Reviewed
  • [Presentation] CYP3A4遺伝的variantsに対する各種競合阻害剤の阻害特性の比較2015

    • Author(s)
      綾華奈子、小林由季、秋好健志、今岡鮎子、日比野英幸、荒木拓也、宮崎光江、F.P.Guengerich、中村克徳、中村智徳、山本康次郎、大谷壽一
    • Organizer
      日本薬学会第135年会
    • Place of Presentation
      神戸
    • Year and Date
      2015-03-26
    • Related Report
      2014 Annual Research Report
  • [Presentation] 各種CYP3A4変異型分子種に対するベラパミルおよびその代謝物のMBI特性2015

    • Author(s)
      秋好健志、大橋拓人、今岡鮎子、日比野英幸、荒木拓也、宮崎光江、F.P.Guengerich、中村克徳、中村智徳、山本康次郎、大谷壽一
    • Organizer
      日本薬学会第135年会
    • Place of Presentation
      神戸
    • Year and Date
      2015-03-26
    • Related Report
      2014 Annual Research Report
  • [Presentation] CYP3A4のMechanism-based inhibition は基質依存的に生じるか2014

    • Author(s)
      石川裕子、秋好健志、今岡鮎子、大谷壽一
    • Organizer
      医療薬学フォーラム2014
    • Place of Presentation
      東京
    • Year and Date
      2014-06-28 – 2014-06-29
    • Related Report
      2014 Annual Research Report
  • [Presentation] CYP3A4変異型分子種におけるtestosterone及びmidazolamの代謝に対する競合阻害剤の阻害強度の比較2014

    • Author(s)
      小縣淳子、秋好健志、今岡鮎子、日比野英幸、荒木拓也、宮崎光江、Guengerich FP、中村克徳、中村智徳、山本康次郎、大谷壽一
    • Organizer
      日本薬学会第134年会
    • Place of Presentation
      熊本市
    • Related Report
      2013 Research-status Report
  • [Presentation] 各種CYP3A4変異型分子に対するグレープフルーツ果汁およびその成分のMBI特性2014

    • Author(s)
      秋好健志、今岡鮎子、日比野英幸、荒木拓也、宮崎光江、Guengerich FP、中村克徳、中村智徳、山本康次郎、大谷壽一
    • Organizer
      日本薬学会第134年会
    • Place of Presentation
      熊本市
    • Related Report
      2013 Research-status Report
  • [Presentation] In vitro データをもとにした、CYP2D6 variants における paroxetine の非線形体内動態の予測2014

    • Author(s)
      丹羽しおり、秋好健志、今岡鮎子、大谷壽一
    • Organizer
      日本薬学会第134年会
    • Place of Presentation
      熊本市
    • Related Report
      2013 Research-status Report
  • [Presentation] 石内美帆、秋好健志、今岡鮎子、大谷壽一2014

    • Author(s)
      Terbinafine のCYP2D6阻害特性に対するCYP2D6遺伝子変異の影響
    • Organizer
      日本薬学会第134年会
    • Place of Presentation
      熊本市
    • Related Report
      2013 Research-status Report
  • [Presentation] 果実成分によるCYP3A4のMBI特性に対する遺伝子変異の影響2013

    • Author(s)
      鈴木恵美、日比野英幸、秋好健志、村瀬沙織、荒木拓也、宮崎光江、Peter Guengerich、中村克徳、中村智徳、山本康次郎、大谷壽一
    • Organizer
      日本薬学会第133年会
    • Place of Presentation
      横浜市
    • Related Report
      2012 Research-status Report

URL: 

Published: 2013-05-31   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi